Xenomics files lawsuit against Sequenom

Xenomics, a developer of trans-renal molecular diagnostic technologies, has filed a complaint against Sequenom, a diagnostic testing and genetics analysis company, in the Supreme Court of New York alleging that Sequenom fraudulently misrepresented to Xenomics the status of its testing for Down syndrome and based upon such conduct, Xenomics was induced to enter into a licensing agreement with Sequenom thereby giving up various valuable patent rights.

In addition, Xenomics is alleging that Sequenom breached the licensing agreement entered into between the parties by fraudulently misrepresenting the status of Sequenom.

Xenomics is seeking money damages together with punitive damages for Sequenom's willful fraud in an amount not to exceed $300 million as well as the termination of the licensing agreement between the parties.

On September 28, 2009, Sequenom announced that the Federal Bureau of Investigation and US Attorney's office were investigating it with respect to its alleged successful Down syndrome test.

http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

Related terms: genetics, investigation, lawsuit, money, new york, patent, technology